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Abstract
Introduction The functional unit of the mammary gland has been
defined as the epithelial cell plus its microenvironment, a
hypothesis that predicts changes in epithelial cell function will
be accompanied by concurrent changes in mammary stroma. To
test this hypothesis, the question was addressed of whether
mammary stroma is functionally altered by the anti-oestrogen
drug tamoxifen.
Methods Forty female rats at 70 days of age were randomised
to two groups of 20 and treated with 1.0 mg/kg tamoxifen or
vehicle subcutaneously daily for 30 days, followed by a three-
day wash out period. Mammary tissue was harvested and
effects of tamoxifen on mammary epithelium and stroma
determined.
Results As expected, tamoxifen suppressed mammary alveolar
development and mammary epithelial cell proliferation. Primary
mammary fibroblasts isolated from tamoxifen-treated rats
displayed a three-fold decrease in motility and incorporated less
fibronectin in their substratum in comparison to control
fibroblasts; attributes indicative of fibroblast quiescence.
Immunohistochemistry analysis of CD68, a macrophage
lysosomal marker, demonstrated a reduction in macrophage
infiltration in mammary glands of tamoxifen-treated rats.
Proteomic analyses by mass spectrometry identified several
extracellular matrix (ECM) proteins with expression levels with
tamoxifen treatment that were validated by Western blot.
Mammary tissue from tamoxifen-treated rats had decreased
fibronectin and increased collagen 1 levels. Further, ECM
proteolysis was reduced in tamoxifen-treated rats as detected
by reductions in fibronectin, laminin 1, laminin 5 and collagen 1
cleavage fragments. Consistent with suppression in ECM
proteolysis with tamoxifen treatment, matrix metalloproteinase-2
levels and activity were decreased. Biochemically extracted
mammary ECM from tamoxifen-treated rats suppressed in vitro
macrophage motility, which was rescued by the addition of
proteolysed collagen or fibronectin. Mammary ECM from
tamoxifen-treated rats also suppressed breast tumour cell
motility, invasion and haptotaxis, reduced organoid size in 3-
dimensional culture and blocked tumour promotion in an
orthotopic xenograft model; effects which could be partially
reversed by the addition of exogenous fibronectin.
Conclusions These data support the hypothesis that mammary
stroma responds to tamoxifen treatment in concert with the
epithelium and remodels to a microenvironment inhibitory to
tumour cell progression. Reduced fibronectin levels and
reduced ECM turnover appear to be hallmarks of the quiescent
mammary microenvironment. These data may provide insight
into attributes of a mammary microenvironment that facilitate
tumour dormancy.
3D: three-dimensional; BrdU: bromodeoxyuridine; DMEM: Dulbecco's modified eagle medium; ECM: extracellular matrix; EDTA: ethylenediamine-
tetraacetic acid; EGF: epidermal growth factor; EGFR: epidermal growth factor receptor; ER: oestrogen receptor; FCS: fetal calf serum; GAPDH: 
glyceraldehyde 3-phosphate dehydrogenase; H&E: haematoxylin and eosin; LN: laminin; MEC: mammary gland epithelial cells; MG: mammary gland; 
MMP: matrix metalloproteinase; MT1-MMP: membrane type 1 matrix metalloproteinase; MW: molecular weight; NBF: neutral buffered formalin; NIH: 
National Institutes of Health; PBS: phosphate buffered saline; PR: progesterone receptor; RCF: relative centrifugal force; SEM: standard error of the 
mean; TGFβ: tumour growth factor beta.Breast Cancer Research    Vol 11 No 1    Hattar et al.
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Introduction
Once thought of as a passive support structure, the mammary
microenvironment is composed of a complex mix of cellular,
structural and soluble components capable of fundamentally
altering mammary epithelial cell specificity and behaviour [1].
Consequently, the functional unit of the mammary gland is now
recognised as the epithelial cell plus its extracellular matrix
(ECM) and stromal and immune cells embedded therein [2].
Fibroblasts are primarily responsible for deposition of the stro-
mal ECM. It is anticipated that for each organ fibroblasts
deposit tissue-specific ECM [3]. The model of dynamic reci-
procity postulates that the microenvironment, in particular the
ECM, exerts an influence on gene expression in the mammary
epithelial cell and, in turn, gene expression of the epithelial cell
influences stromal cells and the composition of the ECM [2,4].
In support of this concept, our laboratory has shown that the
composition of rat mammary ECM is dependent on reproduc-
tive state, demonstrating that the mammary microenvironment,
as with the mammary epithelium, is under endocrine control
[5]. Further, mammary ECM isolated from distinct hormonal
states was found to facilitate epithelial cell proliferation, differ-
entiation, death and glandular reorganisation in 3-dimensional
(3D) cell culture, recapitulating events that occur in vivo with
the pregnancy-involution cycle. Work by others has shown
that the mammary ECM protein fibronectin and its specific
integrin α5β1 are under hormonal control and in turn mediate
hormone response in mammary epithelium, providing further
support for the concept of Dynamic Reciprocity in the mam-
mary gland [6,7].
Given the dynamic and reciprocal relation between ECM and
normal mammary epithelial cells, it is not surprising that the
microenvironment also exerts a significant effect on tumour
cell behaviour [8]. Early evidence for stromal impact on cancer
progression was observed by histological analyses; as wound
healing-associated modifications in stroma, termed desmopla-
sia, were shown to contribute to poor prognosis in many
human cancers, including breast, colon and prostate [9-14].
More surprisingly, even physiological changes in the mammary
microenvironment have been demonstrated to influence
tumour cell progression [5,15-17]. For example, mammary
ECM isolated from mammary glands undergoing weaning-
induced involution promotes breast tumour cell motility and
invasion in vitro and metastasis in a xenograft model of breast
cancer, whereas ECM isolated from quiescent virgin mammary
tissue did not support these tumour cell attributes [15,17].
Mammary involution ECM is characterised in part by partial
proteolysis of fibronectin and laminin, high-fibrillar collagen
content, and increased matrix metalloproteinase (MMP) activ-
ity; all of which have been implicated in tumour progression
[5,17,18]. Thus, evidence suggests that both pathological –
and physiological-induced changes in mammary stroma con-
tribute to breast cancer progression.
Whether the microenvironment can actively inhibit tumour pro-
gression has not been well studied. It is known that tumour
cells can arrive at secondary sites in high numbers but fail to
expand [19] and that microtumours and solitary tumour cells
can reside in a dormant state for decades [20-22]. These data
suggest that the microenvironment can indeed exert a signifi-
cant protective effect. Experimental proof of this principle lies
in studies in which malignant cells undergo a phenotypic rever-
sion to polarised epithelium when exposed to a tissue-normal-
ising ECM milieu [23-25]. Further, morphologically normal
epithelial tissue adjacent to breast tumours can display loss of
heterozygosity similar to that of the tumour, but without mani-
festing tumour cell characteristics [26]. One explanation is
that malignant progression of these mutant, but morphologi-
cally normal, cells is inhibited by the local tissue microenviron-
ment. Cumulatively, these data strongly suggest that the
microenvironment can impart a dormant suppressive pheno-
type on malignant cells.
In this study, we tested the hypothesis that the stromal com-
partment responds with the epithelium to interventions that
reduce breast cancer risk. Specifically, we addressed whether
tamoxifen treatment alters the composition and function of
mammary ECM in a manner consistent with supporting tumour
cell dormancy. Tamoxifen is the endocrine treatment of choice
for pre-menopausal women with breast cancer and a proven
chemopreventive agent in high-risk patients [27]. Its canonical
mechanism is as an anti-proliferative agent in oestrogen recep-
tor (ER) positive mammary tumour cells [28]. Our data support
the hypothesis that mammary stroma responds to tamoxifen
treatment and remodels to an environment that would be inhib-
itory to breast cancer progression.
Materials and methods
Tamoxifen study experimental design
Forty female Sprague-Dawley rats, 73 days of age (Harlan-
Teklad, Indianapolis, IN, USA) were randomised by weight into
two groups of 20. Rats in the tamoxifen group were injected
subcutaneously daily with 1 mg/kg tamoxifen (Sigma, St.
Louis, MO, USA) dissolved in ethanol and suspended in ses-
ame oil. The vehicle control group was injected daily with an
equal volume of ethanol/sesame oil solvent. After 30 days of
treatment, lymph-node-free right inguinal mammary glands
were harvested, snap frozen and stored at -80°C for subse-
quent ECM isolation and biochemical analyses. To limit varia-
tions in ECM composition that may accompany oestrous
cycling in the control group, phase of oestrous cycle was
determined by daily cervical lavages and all control rats were
sacrificed in the dioestrus 1 phase of the cycle, as previouslyAvailable online http://breast-cancer-research.com/content/11/1/R5
Page 3 of 16
(page number not for citation purposes)
described [29]. Cervical tissue was also collected for histolog-
ical confirmation of oestrous cycle. The animal experiments
were performed in duplicate. All animal procedures were per-
formed in compliance with the AMC Cancer Research Insti-
tute and University of Colorado Denver Animal Care and Use
Committees and National Institutes of Health (NIH) Policy on
Humane Care and Use of Laboratory Animals.
Primary fibroblast isolation
Left inguinal mammary glands (lymph nodes removed) were
processed for fibroblast isolation immediately after sacrifice
using a protocol provided by Kornelia Polyak which has been
previously reported [30]. Briefly, the tissue was minced and
incubated in collagenase. After incubation, the tissue was
processed through a series of centrifugations to separate
fibroblasts. Isolated cells were confirmed to be fibroblast-like
when they tested negative for pan-cadherin and pan-cytokera-
tin and positive for vimentin by Western blot analyses (data not
shown), and are referred herein as fibroblasts; however,
endothelial cell specific markers were not evaluated. Fibrob-
lasts, used at passage three, were maintained in Dulbecco's
modified eagle medium (DMEM)/F12 media (Hyclone, Logan,
UT, USA) supplemented with 25 mM Hepes (Sigma, St. Louis,
MO, USA), 2 mM L-glutamine (Sigma, St. Louis, MO, USA),
50 μg/mL gentamicin (Sigma, St. Louis, MO, USA) and 20%
FCS (Sigma, St. Louis, MO, USA).
Fibroblast motility assay
Transwell 8 μm pore filters in a 24-well plate format (Becton
Dickinson, Franklin Lakes, NJ, USA) were overlaid with 50 μL
bovine gelatin, type B (Sigma, St Louis, MO, USA) at a con-
centration of 10 μg/mL and dried overnight. Five × 104 log-
phase primary fibroblasts at passage three were suspended in
incomplete media and plated into the upper chamber. The
lower chamber contained 1% fetal bovine serum as chemoat-
tractant. The number of motile cells, evaluated four hours after
plating, was quantified as previously described [15]. The
assay was performed in quadruplicate and data are expressed
as mean ± standard error of the mean (SEM).
Fibroblast-derived 3-dimensional matrices
Primary mammary fibroblasts were pooled according to group,
and 2 × 105 cells were plated into six-well plates pre-coated
with 50 μl of 2 μg/ml rat tail collagen (BD Biosciences, Bed-
ford, MA, USA). Fibroblasts were cultured for 10 days in com-
plete media, which was changed every two days. To isolate
underlying ECM, fibroblasts were lysed in 20 mM ammonium
hydroxide and 0.5% Triton X-100 followed by several washes
in PBS and water, according to the published protocol by
Cukierman [31]. The cell-free underlying ECM was scraped
from plates and stored at -80°C for proteomic analysis.
Histology
Whole mount mammary glands were fixed in methacarn, proc-
essed in a series of ethanol and xylene (Fisher, Fair Lawn, New
Jersey, USA), stained with alum carmine (Fisher, Fair Lawn,
New Jersey, USA), and bagged in methyl salicylate (Fisher,
Fair Lawn, New Jersey, USA), as previously described [32].
Cervical tissue was also harvested, fixed in 10% neutral buff-
ered formalin (NBF) for 18 hours, paraffin embedded, cut into
5 μm sections and stained with H&E. To control for morpho-
logical differences due to natural variation along the proximal/
distal mammary gland axis, mammary tissue associated with
the dissected lymph regions of gland number 4 were fixed in
10% NBF for 18 hours and processed for H&E staining as
described above. The changes in mammary ductal and alveo-
lar morphology in response to tamoxifen treatment were eval-
uated in these 5 μm H&E-stained sections as previously
described [32].
For detection of fibrillar collagen, 5 μm sections of mammary
tissue were stained with sirius red F3B according to published
methods [33] and counterstained with Weigert's iron haema-
toxylin. Mammary gland collagen staining was classified into
three grades. Grade 1 glands had fat pads composed prima-
rily (more than 50%) of adipocytes and were free of dense
interlobular collagen. Grade 2 glands had mixed fat pad mor-
phology, with both adipocyte and fibrillar collagen-rich
regions. Grade 3 glands had stroma dominated by fibrillar col-
lagen. Collagen scoring was performed on coded slides by
two independent investigators.
Immunohistochemistry
Samples of 4 μm tissue were pretreated in 10 mM sodium cit-
rate at 90°C for 20 minutes. Bromodeoxyuridine (BrdU; BD
Immunocytometry Systems, San Jose, CA, USA, for rat tissue;
Dako, Santa Barbara, CA, USA, for mouse tissue) and the
macrophage marker CD68 (Serotec, Oxford, UK) were
detected with a standard avidin biotin complex-peroxidase
method with 3,3'-diaminobenzidine as the chromagen.
Mammary ECM isolation
Mammary ECM isolation was performed based on a previously
described protocol [5], using pooled inguinal mammary gland
tissue from at least six rats per group. Briefly, frozen inguinal
mammary glands, with lymph nodes removed, were pulverised,
homogenised and extracted in a high salt/N-ethylmaleimide
solution (3.4 M sodium chloride, 50 mM Tris-hydrochloric acid
pH 7.4, 4 mM ethylenediaminetetraacetic acid (EDTA), 2 mM
N-ethylmaleimide) containing protease inhibitor cocktail (100
μg/ml phenylmethylsulphonyl fluoride, 50 μg/ml each of apro-
tinin, leupeptin and pepstatin), at 4°C (chemicals purchased
from Sigma, St Louis, MO, USA). Homogenates were
enriched for ECM by two cycles of centrifugation (relative cen-
trifugal force (RCF)max 110,000 × g, 30 minutes, 4°C). The
ECM-enriched pellets were resuspended in mid-salt/urea
solution with proteinase inhibitor cocktail and extracted over-
night at 4°C. Samples were pelleted at RCFmax 110,000 × g,
and the ECM-enriched supernatants extensively dialysed
(MWCO 12–14,000 kDa, Spectrum) against low salt bufferBreast Cancer Research    Vol 11 No 1    Hattar et al.
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followed by dialysis against sera-free media (DMEM/F12
media (Sigma, St Louis, MO, USA) supplemented with 1 μg/
ml gentamicin) at 4°C. ECM were stored on ice at 4°C and
used within two weeks of isolation. As reported previously,
ECM protein integrity is stable under these storage conditions
[5]. For the in vitro studies, all experiments were performed
with two distinct batches of ECM in at least duplicate.
ECM proteomics
Aliquots of the mammary ECM isolates were subjected to in-
solution tryptic digestion for label-free mass spectrometry-
based analysis. Each sample was reduced and alkylated with
5 mM dithiothreitol and 20 mM iodoacetamide after the addi-
tion of Rapigest (Waters Technologies, Millford, MA, USA) to
0.1%. Trypsinisation was carried out overnight at 37°C and
the reaction stopped by adding formic acid to a final concen-
tration of 1%. Centrifugation was used to remove the hydro-
lytic detergent and sample zip tipped (Millipore, Temecula, CA,
USA) to remove salts.
For electrospray ionisation mass spectrometry, each of the
samples (2 μL) was injected onto a reverse-phase column
using a chilled (9°C) autosampler (Eksigent; Dublin, CA, USA)
connected to a high-performance liquid chromatography sys-
tem run at 0.12 μL/minute before a passive split that resulted
in about a 400 nL/minute post-split flow (Aligent; Santa Clara,
CA, USA). A gradient of 12% to 30% acetonitrile (40 minutes)
was applied over a two-hour run for peptide separation. The
column effluent was coupled directly to a LTQ XL Linear Ion
Trap mass spectrometer (Thermo/Finnigan; San Jose, CA,
USA) with an in-house built nanospray ion source. Data acqui-
sition was performed using the Xcalibur (version 2.0.6) soft-
ware supplied with the instrument. The 60 minute liquid
chromatography (LC) runs were monitored by sequentially
recording the precursor scan (MS) followed by three collision-
induced dissociation acquisitions (MS/MS). Singly charged
ions were excluded from collision induced disassociation
(CID) selection. Normalised collision energies were employed
using helium as the collision gas. An in-house script was used
to create de-isotoped centroided peak lists from the raw spec-
tra (mgf format). These peak lists were searched against the
SwissProt (V51.6) database using an in-house developmental
Protein Prospector LC Batch-Tag Web (Version 4.25.2,
UCSF, San Francisco, CA, USA) and an in-house Mascot
server (Version 2.2, Matrix Science, Boston, MA, USA). For
searches mass tolerances were ± 0.6 Da for MS peaks (+1
13C option), and ± 0.6 Da for MS/MS fragment ions. Trypsin
specificity was used allowing for one missed cleavage. The
modifications of met oxidation, protein N-terminal acetylation,
peptide N-terminal pyroglutamic acid formation were allowed
for. Samples were searched against all rat and mouse entries
in the protein database.
Western blot analysis
Tissues from mammary glands were analysed by Western Blot
as previously described [5]. The following antibodies were
used: polyclonal rabbit anti-rat fibronectin (1:250 Life Technol-
ogies, Gaithersburg, MD, USA), polyclonal rabbit anti-laminin
(1:500 Novus Biologicals, Littleton, CO, USA), mouse anti-
laminin 5 (γ2 chain) monoclonal antibody (1:1000, Chemicon
International, Temecula, CA, USA), collagen 1 (1:1000,
Abcam, Cambridge, MA, USA) and protein A secondary anti-
body (1:10,000 Amersham, Piscataway, NJ, USA). Mono-
clonal mouse anti-glyceraldehyde 3-phosphate
dehydrogenase (GAPDH; 1:500 Amersham, Piscataway, NJ,
USA) followed by an anti-mouse secondary (1:5,000 Santa
Cruz Biotechnology, Santa Cruz, CA, USA) was used for pro-
tein loading controls. Signal was obtained using ECL western
detection kit (Amersham, Piscataway, NJ, USA). For fibronec-
tin and collagen 1 Westerns, 3.3 μg of respective tissue sam-
ples were loaded per lane. For laminin (LN) westerns and
zymogen assays, 9.5 μg of respective tissue samples were
loaded per lane.
Zymogen assay
Substrate gel analyses were performed as described [15].
Briefly, ECM samples loaded by equal protein were electro-
phoresed under non-reducing conditions on a 7.5% SDS-
PAGE containing 3 mg/ml porcine gelatin (Sigma, St. Louis,
MO, USA). Gels were incubated at 37°C for 72 hours in sub-
strate buffer. Proteinase activity was visualised by Coomassie
Blue 250 staining. Zymogen activity appears as a cleared
band in a dark background. Semi-quantitative data was
obtained by scanning densitometry of four independent lanes
per condition with data analysed using BioRad Quantity One
software (Bio-Rad, Hercules, CA, USA).
Cell lines
J774 murine macrophage cells, a generous gift from Dr Doug-
las Graham, were cultured in DMEM/high glucose medium
(Hyclone Laboratories, Logan, Utah, USA) supplemented with
10% heat-inactivated FCS as previously described [34].
MCF-12A cells are a non-tumourigenic human immortalised
mammary epithelial cell line [35]. V12 Ras-transformed MCF-
12A cells were previously described [36]. MCF-12A and
MCF-12A-ras cells were grown in complete media consisting
of Ham's F12/DMEM (Gibco, Carlsbad, CA, USA) containing
100 ng/ml cholera toxin (Gibco/BRL, Carlsbad, CA, USA), 0.5
μg/ml hydrocortisone (Sigma, St. Louis, MO, USA), 10 μg/ml
insulin (Sigma, St. Louis, MO, USA), 20 ng/ml epidermal
growth factor (EGF) (Sigma, St. Louis, MO, USA) and 5%
horse serum (Gibco/BRL, Carlsbad, CA, USA). MDA-MB-231
cells (ATCC, Manassas, VA, USA), a human breast cancer cell
line, were passaged into nude mice (mammary fat pad) and
back out to plastic for at least four cycles as previously
described [17]. The resulting variant cell line, which was
enriched in the ability to grow in the fat pad was carried in
MEM Alpha Media (Gibco, Carlsbad, CA, USA) completedAvailable online http://breast-cancer-research.com/content/11/1/R5
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with 2.2 g/L of sodium bicarbonate, 1% Hepes, 1% L-
glutamine, 10% heat inactivated FCS, 1 μg/ml of insulin, 1%
sodium pyruvate and 1% non-essential amino acids.
Transwell filter assays
Motility assay
Log-phase murine macrophage J774 cells (1 × 105) were sus-
pended in 200 μL of DMEM/high-glucose medium (Hyclone
Laboratories, Logan, Utah, USA) and plated on transwell 8 μm
pore filters in a 24-well plate format (Becton Dickinson, Frank-
lin Lakes, NJ, USA). The lower chamber contained 800 μL of
10 μg/mL control or tamoxifen mammary matrix with or without
10 μg/mL of rat tail collagen type1 (BD Biosciences, Bedford,
MA, USA), 10 μg/mL of bovine skin gelatin, type B (Sigma, St.
Louis, MO, USA) or 10 μg/mL of human plasma fibronectin
(Collaborative Biochemical, Bedford, MA, USA). Eight hours
post-plating, cells were fixed with 10% NBF, stained with
0.1% crystal violet and number of motile cells quantitated as
previously described [15]. For tumour cell motility assays, log
phase MDA-MB-231 cells (5 × 104 cells) were suspended in
10  μg/mL control or tamoxifen mammary gland ECM, and
overlaid onto transwell 8 μm pore filters as described above.
In the lower chamber, 1.0% horse serum was used as a che-
moattractant and number of motile cells evaluated after 21
hours after plating. Motility assays were performed in quadru-
plicate and data are expressed as mean ± SEM.
Invasion assay
Transwell 8 μm pore filters in 24-well plate format (BD Bio-
sciences, Bedford, MA, USA), were overlaid with 50 μL con-
trol or tamoxifen mammary ECM at a concentration of 200 μg/
mL and dried overnight. Log-phase MCF12A-ras cells (5 ×
104 cells), were suspended in incomplete media and plated
into the upper chamber. The lower chamber contained 0.5%
horse serum as chemoattractant. The number of invasive cells,
evaluated 24 hours post plating, was quantified as previously
described [15]. The assay was performed in quadruplicate
and data are expressed as mean ± SEM.
Haptotaxis assay
Transwell 8 μm pore filters were underlaid (coated on the bot-
tom of the filter) with 50 μL control or tamoxifen mammary
ECM at a concentration of 75 μg/mL and dried overnight. Log-
phase MDA-MB-231 cells (5 × 104 cells) were suspended in
incomplete media and plated into the upper chamber. The
lower chamber contained incomplete media; the ECM on the
filter served as chemoattractant. The number of invasive cells,
evaluated four hours post plating, was quantified as described
above. For all transwell filter assays, differences between con-
trol and experimental conditions were determined using the
two-tailed t-test.
3-dimensional culture model
Ras-transformed MCF-12A and MDA-MB-231 cells were cul-
tured in 3D culture as previously described [5]. Briefly, log-
phase cells were harvested and overlaid onto 2 mm thick
matrix pads at cell concentrations of 4.5 × 104 (MCF-12A) or
1.5 × 104 (MDA-MB-231) or pre-coated with respective matri-
ces with and without 20 μg/mL fibronectin (Collaborative Bio-
chemical, Bedford, MA, USA) before overlaying onto the
matrix pad, using a 96-well format (Sarstedt, Newton, NC,
USA). The matrix substratum was composed of 50 μL of nul-
liparous or tamoxifen-treated rat mammary gland ECM (nor-
malised for total protein concentration) mixed 1:1 with Matrigel
(BD Biosciences, San Jose, CA, USA) to facilitate polymerisa-
tion of endogenous mammary ECM. For control conditions,
the pad was composed of Matrigel, without endogenous mam-
mary ECM and controlled for total protein concentration. For
MCF-12A cells, 5% horse serum was added to the matrix
pads. 3D culture assays were performed in triplicate and each
experiment performed in duplicate with two different batches
of endogenous mammary ECM.
Image acquisition and quantitation
Five micron sections of 3D organoids capturing top, middle
and bottom representative areas of the matrix pad were H&E
stained and imaged at 20× using an Aperio Scan Scope T3
System, (Vista, CA, USA) at a resolution of 1 pixel/0.5 u and
then down-sampled to a resolution of 1 pixel/2.4 u. Primary
identification of cell clusters (organoids) was accomplished
using NIH ImageJ (version 1.41o with Java 1.6.0_10.) that had
been customised for colorimetric, size and circularity threshold
gating steps using custom written plug-ins in the Java pro-
gramming language. These image analysis algorithms were
designed to identify and quantify immunohistochemical and
morphological characteristics of 3D organoids. Image pre-
processing procedures were applied to identify and remove
from subsequent analyses images with scanning and staining
errors. Images that passed these filters were analysed using a
series of algorithms. The primary image algorithms relied on
identifying histochemical features through colorimetric thresh-
olds. Secondary pass morphometric quantifications focused
on area and circularity measurements for feature identification.
This automated algorithmic-targeted image analysis was uti-
lised to eliminate intra-observer and inter-observer variability
and results in a repeatable mathematically quantifiable set of
data. The number of organoids analysed was 1456 in the
Matrigel group, 1516 in the control mammary ECM group and
709 in the tamoxifen mammary ECM group. Mean cell cluster
sizes were compared across treatment groups. Given that the
data were not normally distributed, significance was evaluated
using the Kruskal-Wallis, non-parametric test. Alternatively,
308 tamoxifen organoids and 241 tamoxifen plus fibronectin
organoid images were captured under light microscopy and
NIH ImageJ (version 1.41o with Java 1.6.0_10.) utilised to
determine the average area per organoid, and differences
determined using the Mann-Whitney U Test.Breast Cancer Research    Vol 11 No 1    Hattar et al.
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Xenograft model
Forty eight-week old female homozygous Nu/Nu athymic nude
mice (NCI, Frederick, MD, USA) were randomised by weight
into two groups of 20. The animals were anaesthetised using
isoflurane (Minrad, Inc., Bethlehem, PA, USA). Log-phase
MDA-MB-231 cells were mixed with 270 μg/mL of control or
tamoxifen rat mammary ECM at a concentration of 1.0 × 105
cells/μL matrix. Of the cell/matrix mix (2 × 106 total cells), 20
μL were back-loaded into a 3/10 cc insulin syringe with a 29
gauge 1/2 inch needle (BD Biosciences, San Jose, CA, USA)
and injected into the fat pad of mammary gland number 4 [37].
For fibronectin experiments, MDA-MB-231 cells were mixed
with incomplete α-MEM media with or without 20 μg/ml
fibronectin (Collaborative Biochemical, Bedford, MA, USA)
just before fat pad injection, with 10 mice per group. Tumour
growth was measured using calipers twice weekly. Animals
were sacrificed at six weeks post tumour cell injection.
Tumours were excised, weighed and final tumour volume cal-
culated (4/3πR2h). Statistical analyses were performed using
the Kruskal-Wallis test and the Wilcoxon nonparametric anal-
ysis.
Results
Characterisation of mammary and cervical tissue in 
tamoxifen-treated rats
Tamoxifen is known to be an oestrogen antagonist in the mam-
mary gland and acts to block proliferation of ER-positive epi-
thelial cells. As expected, in comparison to control rats, the
mammary epithelium in the tamoxifen-treated rats had a signif-
icant reduction in alveolar development (Figure 1a, upper pan-
els). Morphometric analysis demonstrated that only 25% of
vehicle-treated rats had mammary glands lacking well-devel-
oped alveoli, whereas 75% of mammary glands from
tamoxifen-treated rats had mammary glands lacking alveoli
(Figure 1a, graph). Consistent with the loss of mammary alve-
oli in the tamoxifen-treated rats, mammary epithelial cell prolif-
eration, as measured by BrdU incorporation, was significantly
reduced (Figure 1b, upper panels; BrdU quantification is
shown in Figure 1b, lower panel). In the uterus, tamoxifen is an
oestrogen agonist and one of tamoxifen's known side effects
in women is an increase in uterine tumours. As previously
reported by others, we found that tamoxifen-treated rats did
not cycle through oestrous and the uterine and cervical tissues
from these rats displayed proliferative phenotypes (Figure 1c),
indicating that, as in women, tamoxifen acts as an oestrogen
agonist in the rat uterus [38].
Characterisation of mammary stroma composition
To begin to address the question of whether tamoxifen alters
mammary stroma, primary fibroblasts were isolated from mam-
mary glands of control and tamoxifen-treated rats. Fibroblast
cells were characterised as positive by immunohistochemistry
staining for vimentin and smooth muscle actin and by lack of
pan-cadherin staining (data not shown). Fibroblast motility was
assessed as a functional marker of cell activity. Although inter-
Figure 1
Effects of tamoxifen on proliferation of mammary and cervical epithe- lium Effects of tamoxifen on proliferation of mammary and cervical epithe-
lium. (a) upper panels: Whole mount mammary gland micrographs from 
control (Ctl) and tamoxifen-treated (Tam) rats showing loss of alveoli 
with tamoxifen treatment 40× magnification. (a) lower panel: Graph 
depicting percentage of rats in each group with dominant ductal, mixed 
or alveolar mammary gland morphology. (b) upper panels: Bromodeox-
yuridine (BrdU) positive proliferating cells detected by immunohisto-
chemistry. Arrow shows brown staining BrdU-positive cell. 400× 
magnification. (b) lower panel: Quantitation of proliferating mammary 
epithelial cells in control (n = 12) and tamoxifen (n = 12) treated rats, 
*p < 0.001. (c) Cervical histology of control and tamoxifen-treated rats. 
Arrow shows thick stratum germinativum layer in tamoxifen-treated rats 
consistent with hormone stimulation.Available online http://breast-cancer-research.com/content/11/1/R5
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animal variation in fibroblast motility was high, overall mam-
mary fibroblasts isolated from the tamoxifen-treated animals
displayed a significant three-fold decrease in transwell filter
motility compared with control mammary fibroblasts (Figure
2a).
Fibroblasts are the major producers of mammary interlobular
and periductal ECM and the motility data suggested that ECM
production might be similarly altered by tamoxifen treatment.
To address this question, the ECM secreted by primary fibrob-
lasts in culture and incorporated into a 3D insoluble matrix was
harvested and run on a 1D-gel. A prominent band of about
250 kD was decreased in the tamoxifen group (Figure 2b,
arrow). This band was excised and found to contain fibronectin
by mass spectrometry. These data show that in vitro, mam-
mary fibroblasts isolated from tamoxifen-treated rats are less
motile and incorporate less fibronectin into the insoluble matrix
than fibroblasts isolated from vehicle control rats, data consist-
ent with tamoxifen treatment causing fibroblast quiescence.
Tissue macrophages are a stromal cell type whose presence
correlates directly with breast cancer progression in women
and in rodent models [39]. To determine whether tamoxifen
treatment influenced the macrophage content of the mammary
gland, immunohistochemistry analysis of the macrophage lys-
osomal marker CD68 was performed (Figure 2c, upper pan-
els). Quantification of CD68 staining demonstrated that the
CD68 signal was significantly decreased in mammary glands
of tamoxifen-treated rats (Figure 2c, graph). Given that ECM
proteins can function as attractants for macrophages, we next
determined whether isolated ECM preparations from control
and tamoxifen-treated rats differentially attract macrophages in
a transwell filter assay. Using the isolated mammary matrices
as chemoattractants, the motility of J774 cells, a mouse mac-
rophage cell line, was suppressed by tamoxifen ECM in com-
parison with control ECM (Figure 3). These observations
suggest that changes in mammary ECM composition with
tamoxifen treatment could provide a plausible mechanism by
which macrophage number is reduced in the mammary glands
of tamoxifen-treated rats.
Tissue matrix proteomics
To identify prominent ECM proteins that compose the rat
mammary gland stroma and which might be differentially
expressed with tamoxifen treatment, ECM proteins were
extracted from mammary glands of control and tamoxifen-
treated rats and identified by tandem mass spectrometry.
Prominent ECM proteins identified included fibronectin, colla-
gen chains α-1(I), α-2(XIV) and α-2(I), laminin chains α4, β1,
β2 and γ1, nidogen 1 and fibrillin 1. In addition, numerous
matrix proteoglycans were identified in the mammary ECM,
including decorin, perlecan, lumican, biglycan, mimecan and
periostin (Table 1).
Figure 2
Influence of tamoxifen treatment on mammary stromal fibroblasts and  macrophages Influence of tamoxifen treatment on mammary stromal fibroblasts and 
macrophages. (a) Motility of primary mammary fibroblasts isolated from 
individual control rats (Ctl; n = 7), tamoxifen-treated rats (Tam; n = 10), 
and pooled populations (insert). (b) One-dimensional gel of extracellu-
lar matrix (ECM) proteins laid down in culture by primary mammary 
fibroblasts isolated from control and tamoxifen-treated rats. Arrow 
shows about a prominent 250 kD band identified as containing 
fibronectin (FN) by mass spectrometry, which is present in control ECM 
and greatly reduced in tamoxifen ECM. Lane 3 depicts molecular 
weight (MW) marker. (c) upper panel: 5 μm representative sections of 
mammary glands stained for CD68, a macrophage lysosomal-associ-
ated protein. 400× magnification. (c) lower panel: Quantitation of 
CD68 positive mammary cells in control (n = 6) and tamoxifen-treated 
(n = 6) rats demonstrates significantly fewer macrophages with 
tamoxifen treatment (*p = 0.013).Breast Cancer Research    Vol 11 No 1    Hattar et al.
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To determine whether the relative abundance of the identified
mammary ECM proteins differed with tamoxifen treatment,
several of the ECM proteins identified by proteomics were
evaluated by Western blot. Mammary tissue from tamoxifen-
treated rats had decreased levels of fibronectin (Figure 4a),
data consistent with the in vitro fibroblast data described in
Figure 2b. In addition, tamoxifen treatment resulted in a mod-
est increase in the basement membrane protein laminin 1, and
a decrease in total laminin 5 levels (Figure 4a). Western blot
analysis revealed that tamoxifen treatment increased levels of
the intra-lobular and inter-lobular ECM protein collagen 1 (Fig-
ure 4b, left panel). Tissue collagen deposition, as measured by
Picro-sirius red staining, confirmed elevated levels of fibrillar
collagen in the mammary stroma of tamoxifen-treated rats (Fig-
ure 4b, right panels and Table 2). Further, Western blot analy-
ses demonstrated a generalised decrease in mammary ECM
proteolysis with tamoxifen treatment, as evidenced by an
increase in the ratio of high to low molecular weight species of
fibronectin, laminin 1, laminin 5 and collagen 1 (Figures 4a, b).
Activity of MMP-2, an MMP found in high levels in virgin rat
mammary glands and implicated in mammary ECM proteoly-
sis, was evaluated in mammary tissue of control and tamoxifen-
treated rats. Total MMP-2 and active MMP-2 were found to be
decreased in mammary tissue of tamoxifen-treated rats (Figure
4c, left panel). Quantitation by densitometry showed about a
45% decrease in total MMP-2 (Figure 4c, upper right panel)
and more than a 85% reduction in the cleaved active form of
MMP-2 (Figure 4c, lower right panel). These data show that
the decrease in ECM proteolysis in mammary glands of
tamoxifen-treated rats correlated with concurrent decreases in
MMP-2 levels and activity.
In vitro functional evaluations of ECM
As confirmed by Western blot analyses, prominent differences
between control and tamoxifen mammary ECM composition
were the presence of high levels of intact fibrillar collagen in
mammary tissue of tamoxifen-treated rats and the presence of
partially proteolysed collagen and elevated levels of fibronec-
tin in control mammary glands. The question of whether these
ECM components influence macrophage motility was evalu-
ated next. To reconstitute the high levels of collagen 1
observed in tamoxifen ECM, 10 μg/ml fibrillar collagen 1 was
added to control ECM. The addition of fibrillar collagen was
found to suppress J774 macrophage cell motility compared
with control ECM alone (Figure 5a). Conversely, the addition
Figure 3
Tamoxifen extracellular matrix (ECM) recruits fewer macrophages than  control ECM in a transwell filter assay Tamoxifen extracellular matrix (ECM) recruits fewer macrophages than 
control ECM in a transwell filter assay. (a) Photomicrographs of tran-
swell filters showing that J774 macrophage cells are less chemotactic 
towards tamoxifen ECM compared with control ECM. 100× magnifica-
tion. (b) Quantitation of J774 cell motility demonstrates significantly 
reduced chemotaxis towards tamoxifen ECM. *p = 0.003.
Table 1
Mammary ECM proteins identified by mass spectrometry
Swiss-Prot accession # Protein
[Swiss-Prot:Q80X19] Collagen alpha-1(XIV)
[Swiss-Prot:P02454] Collagen alpha-1(I)
[Swiss-Prot:P02466] Collagen alpha-2(I)
[Swiss-Prot:Q61554] Fibrillin 1
[Swiss-Prot:Q9WVH8] Fibulin-5
[Swiss-Prot:P04937] Fibronectin
[Swiss-Prot:P97927] Laminin subunit alpha-4
[Swiss-Prot:P02469] Laminin subunit beta-1
[Swiss-Prot:P15800] Laminin subunit beta-2
[Swiss-Prot:P15800] Laminin subunit beta-2
[Swiss-Prot:P02468] Laminin subunit gamma-1
[Swiss-Prot:P47853]B i g l y c a n
[Swiss-Prot:Q01129]D e c o r i n
[Swiss-Prot:Q9QZZ6] Dermatopontin
[Swiss-Prot:P51886]L u m i c a n
[Swiss-Prot:Q62000]M i m e c a n
[Swiss-Prot:Q05793]P e r l e c a n
[Swiss-Prot:P09650] Mast cell protease 1
[Swiss-Prot:O88766] Neutrophil collagenase
[Swiss-Prot:P10493]N i d o g e n - 1
[Swiss-Prot:Q62009] Periostin
[Swiss-Prot:P29457] Serpin H1 precursorAvailable online http://breast-cancer-research.com/content/11/1/R5
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of 10 μg/ml denatured collagen to tamoxifen mammary ECM
was found to stimulate macrophage motility (Figure 5b). Given
that fibronectin levels were higher in control ECM than
tamoxifen ECM, the effect of 10 μg/ml fibronectin on macro-
phage motility was also investigated. We found that the addi-
tion of fibronectin to tamoxifen ECM had a modest but
statistically significant stimulatory influence on J774 cell motil-
ity when compared with tamoxifen ECM alone (Figure 5c).
Cumulatively, these data suggest that the high level of intact
collagen and reduced level of fibronectin in the mammary tis-
sue of tamoxifen-treated rats contributes to the reduced
number of macrophages observed in mammary glands of
tamoxifen-treated rats.
To address whether mammary ECM isolated from tamoxifen-
treated rats inhibits metastatic-attributes of epithelial tumour
cells in vitro, the effects of control and tamoxifen ECM on
mammary tumour cell invasion, motility and haptotaxis were
evaluated. In a transwell filter assay, the invasiveness of Ras
transformed mammary epithelial MCF-12A cells was reduced
two-fold on tamoxifen ECM compared with control ECM (Fig-
ure 6a). Differences in motility were not observed (data not
shown). These functional analyses were extended to the highly
metastatic human breast cancer MDA-MB-231 cells. MDA-
MB-231 cells had reduced motility on the tamoxifen ECM (Fig-
ure 6b), but no change in invasion (data not shown). The hap-
totactic properties of the isolated mammary ECM were
evaluated using mammary ECM as the chemoattractant. MDA-
MB-231 cells displayed a three-fold reduction in haptotactic
properties towards tamoxifen ECM (Figure 6c). Cumulatively,
these data suggest a partial suppression of the metastatic
phenotype by tamoxifen ECM.
To further characterise the effects of these ECM matrices on
tumour cell behaviour, 3D cell culture assays were performed.
When plated onto control ECM, MCF-12A-Ras cells dis-
played an aggressive phenotype characterised by disorgan-
ised structuring and invasive filapodia (Figure 7a, left panel). In
contrast, when plated onto tamoxifen ECM, these same cells
formed compacted smooth-surfaced multicellular clusters
lacking invasive filapodia (Figure 7a, right panel). H&E stained
4 μm sections of 3D organoids confirmed the observation that
tamoxifen ECM induced small spheroid shaped organoids
(Figure 7b). Quantitative morphometric analyses of organoid
size demonstrated that the average size of organoids plated
onto tamoxifen ECM was 2.6-fold smaller than organoids on
control ECM (Figure 7c). Even very aggressive MDA-MB-231
cells had a subtly altered 3D phenotype on the tamoxifen
ECM. These cells were more clustered and cuboidal in
appearance than when plated on the control ECM, indicating
induction of an epithelial-like morphology (data not shown).
The 3D culture data corroborate the transwell filter assay data
and show that the tamoxifen ECM fails to support tumour cell
motility and invasion.
Figure 4
Mammary extracellular matrix (ECM) proteolysis is reduced with  tamoxifen treatment Mammary extracellular matrix (ECM) proteolysis is reduced with 
tamoxifen treatment. (a) Western blot analyses of fibronectin, laminin 1 
and laminin 5 in mammary tissue from control and tamoxifen-treated 
rats, with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as 
loading control. (b) Fibrillar collagen detected by Western blot (left 
panel) and in 5 μm Picro-sirius red stained mammary gland sections. 
(c) Matrix metalloproteinase (MMP) 2 activity detected by zymography, 
with total MMP-2 levels and active MMP-2 levels quantified by scan-
ning densitometry (*p = 0.005 and *p < 0.0001, respectively).Breast Cancer Research    Vol 11 No 1    Hattar et al.
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To evaluate the contributions of individual ECM proteins to
tumour organoid formation, reconstitution experiments were
performed with fibronectin and collagen 1. The addition of
high molecular weight fibronectin to tamoxifen matrix was
found to consistently increase organoid size in 3D culture, but
the increase in size was modest (Figure 7d). Further, an
increase in local invasion was observed with fibronectin (data
not shown). These data suggest that an increase in fibronectin
alone does not wholly account for the aggressive phenotype
displayed by MCF-12A-Ras cells plated on control ECM. Of
interest, the addition of fibrillar collagen to control matrix dis-
rupted 3D organoid formation, thus the contribution of colla-
gen to the suppressive microenvironment could not be
evaluated in this model (data not shown).
In vivo functional evaluation of ECM
Based on the demonstration that tamoxifen ECM reduced the
aggressive characteristics of two transformed breast cancer
cell lines in multiple cell culture models, we investigated
whether tamoxifen ECM could decrease tumour promotion in
vivo. For this study, MDA-MB-231 cells were mixed with mam-
mary ECM from control and tamoxifen-treated rats and
injected into the inguinal fat pads of female athymic mice. By
seven weeks after tumour cell injection, tumour incidence was
the same between groups; however, mice injected with
tumour cells plus tamoxifen ECM had tumours that were three
times smaller than those injected with tumour cells mixed with
control ECM (Figure 8a). To determine whether the elevated
levels of fibronectin in control mammary ECM influence tumour
size in this xenograft model, as suggested by the 3D organoid
data, MDA-MB-231 cells were treated with 20 μg/ml fibronec-
tin before mammary fat pad injection (Figure 8b). Tumour size
was increased by fibronectin across all time points, however,
because of a large variation in tumour size within a group,
these data did not reach statistical significance.
Discussion
In this paper we characterised the tissue microenvironment
associated with quiescent mammary epithelium. Mammary
quiescence was induced with the anti-oestrogen tamoxifen, an
agent known to suppress proliferation of normal mammary epi-
thelium and ER-positive tumour cells [40]. In our study, in addi-
tion to the expected anti-proliferative effects of tamoxifen on
mammary epithelium, tamoxifen treatment was found to induce
pleiotrophic changes in the mammary microenvironment.
These changes included inhibition of fibroblast motility and
fibronectin incorporation into the substratum, a decrease in
macrophage number, a reduction in MMP-2 activity and mark-
edly less proteolysis of the ECM proteins fibronectin, laminin
1, laminin 5 and collagen 1. This response of the mammary
stroma to tamoxifen treatment provides further evidence for
the hypothesis that dynamic and reciprocal interactions occur
between epithelium and stroma, and that these interactions
dictate epithelial cell function [4,41]. Further, this study dem-
onstrates the plasticity of the adult mammary stroma, which
has significant implications for stromal-targeted therapeutics.
ECM proteins represent a dominant component of the stromal
microenvironment and ECM composition, organisation, cross
linking and turnover are attributes determined primarily by stro-
mal cells. Thus, ECM composition can be considered as a
read-out of changes in stromal cell function. As such, we eval-
uated whether tamoxifen treatment altered functional
a t t r i b u t e s  o f  m a m m a r y  E C M .  M a t r i x  p r o t e i n s  i s o l a t e d  f r o m
tamoxifen-treated rats were found to suppress macrophage
and breast tumour cell motility, tumour cell invasion and hapto-
taxis in transwell filter assays, to significantly reduce the size of
tumour cell organoids in 3D culture, and to inhibit tumour pro-
gression in a xenograft model of breast cancer. Mammary
ECM isolated from control rats did not have these attributes.
These data indicate that tamoxifen modifies the mammary
microenvironment in a manner consistent with tumour sup-
pression, which may shed light on tumour dormancy, the latent
phase that occurs between treatment and disease progres-
sion. Relapse from dormancy can occur after prolonged peri-
ods of disease-free survival, and is a particular problem in
breast cancer [20,21].
Using tamoxifen-induced mammary quiescence as an in vivo
model for tumour dormancy, we identified several candidate
stromal mediators of tumour quiescence. We observed a
decrease in total fibronectin in mammary tissue with tamoxifen
treatment and reduced fibronectin secretion by fibroblasts iso-
lated from mammary glands of tamoxifen-treated rats. In rodent
models, fibronectin mRNA expression is upregulated during
periods of high proliferation such as puberty and pregnancy,
Table 2
Fibrillar collagen content of mammary glands
Grade of collagen depositiona Control group Tamoxifen group
Grade I 5 (23%) 0 (0%)
Grade II 12 (54%) 9 (38%)
Grade III 5 (23%) 15 (62%)
a Grade I glands are at least 50% adipocyte-rich stroma and devoid of dense fibrillar collagen deposition. Grade II glands have moderate levels of 
dense fibrillar collagen or areas with mixed collagen densities and Grade III glands have at least 50% of glands filled with dense fibrillar collagen 
deposition.Available online http://breast-cancer-research.com/content/11/1/R5
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and suppressed during gland involution following weaning
[5,6,42]. Further, the addition of fibronectin to Matrigel in a 3D
culture model stimulated mammary epithelial cell proliferation
and increased acinar size [43]. These observations implicate
fibronectin as a key ECM mediator of mammary epithelial cell
proliferation in vivo. Further, under adverse conditions such as
hypoxia, fibronectin can act as a pro-survival protein due to
upregulation of α5β1 integrin. For example, oncogenic activa-
Figure 5
Macrophage chemotaxis is influenced by the denatured state of colla- gen 1 and fibronectin (FN) levels Macrophage chemotaxis is influenced by the denatured state of colla-
gen 1 and fibronectin (FN) levels. (a) upper panel: Photomicrograph of 
transwell filter showing inhibition of J774 cell motility when 10 μg/ml 
fibrillar collagen 1 is added to control extracellular matrix (ECM) and 
used as chemoattractant. 100× magnification. (a) lower panel: Quanti-
tation of data demonstrates significantly reduced chemotaxis towards 
collagen 1. *p < 0.0001. (b) upper panel: Photomicrograph showing 
that 10 μg/ml denatured collagen (gelatin) added to tamoxifen ECM as 
chemoattractant increases J774 macrophage cell motility. 100× magni-
fication. (b) lower panel: Quantitation of data demonstrates significantly 
increased chemotaxis towards denatured collagen, *p < 0.0001. (c) 
upper panel: Photomicrograph showing that 20 μg/ml FN added to 
tamoxifen ECM increases J774 cell motility. 100 × magnification. (c) 
lower panel: quantitation of data demonstrates significantly increased 
chemotaxis towards FN. *p = 0.0004.
Figure 6
Mammary extracellular matrix (ECM) from tamoxifen-treated rats sup- presses metastatic attributes of transformed mammary epithelial cells in  comparison with ECM from control rats Mammary extracellular matrix (ECM) from tamoxifen-treated rats sup-
presses metastatic attributes of transformed mammary epithelial cells in 
comparison with ECM from control rats. (a) MCF-12A-Ras cell invasion 
through 8 μm transwell filter pores occluded with 200 μg/ml mammary 
ECM was suppressed in response to tamoxifen in comparison with 
control ECM. *p < 0.024. (b) Motility of MDA-MB-231 cells was inhib-
ited in response to filters coated with 10 μg/ml tamoxifen ECM com-
pared with control ECM. *p < 0.005. (c) Using mammary matrices as 
chemoattractant, MDA-MB-231 cells were less motile towards 
tamoxifen ECM. *p < 8.3E-5.Breast Cancer Research    Vol 11 No 1    Hattar et al.
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tion of the receptor tyrosine kinase ERBB2 contributes to
tumour cell resistance to hypoxia by inducing the α5β1
integrin fibronectin receptor, which increases cell adhesion
and survival [44]. In a pancreatic tumour model, fibronectin
interaction with α5β3 caused transactivation of the insulin-like
growth factor-1 receptor and increased tumour cell survival
[45]. Additional roles for fibronectin in promoting tumour cells
are suggested by data demonstrating that proteolytic process-
ing of fibronectin induces breast tumour cell motility, invasion
and activation of MMP-9 [15,16].
Fibronectin has also been implicated directly in the induction
and regulation of dormancy. In cell culture studies, downregu-
lation of β1 integrin induced invasive fibroblast-like breast
tumour cells to revert to polarised cells capable of contributing
to acinar-like epithelium in vitro [24]. In a head and neck carci-
noma model, α5β1 integrin engagement with fibronectin
matrix promoted tumour cell proliferation, whereas disruption
of this ECM interaction suppressed extracellular signal-regu-
lated kinase activation and induced a dormant-like state
Figure 7
Mammary extracellular matrix (ECM) isolated from tamoxifen-treated  rats inhibits tumour cell invasion in 3-dimensional (3D) culture Mammary extracellular matrix (ECM) isolated from tamoxifen-treated 
rats inhibits tumour cell invasion in 3-dimensional (3D) culture. (a) 
Whole-mount 3D organoid images of MCF12A-Ras cells plated onto 
control and tamoxifen derived mammary ECM. Left panel arrow depicts 
commonly occurring tumour cell filapodia invading control ECM. Right 
panel shows small compacted 3D organoids that formed on mammary 
ECM isolated from tamoxifen treated rats. (b) 5 μm H&E-stained sec-
tions of organoids on control and tamoxifen ECM 200× magnification. 
Arrow depicts locally invasive tumour cells present in control ECM cul-
tures. (c) Quantitation of organoid size that developed on control mam-
mary ECM, tamoxifen ECM and Matrigel. Tamoxifen and Matrigel 
organoid size do not differ, but are different from control ECM organoid 
size. *p < 0.0001. (d) upper panel: The addition of 20 μg/ml fibronectin 
(FN) to tamoxifen ECM increased organoid size by about 20%. (d) 
lower panel: Quantitation of organoid size. *p < 0.002.
Figure 8
Mammary extracellular matrix (ECM) isolated from tamoxifen-treated  rats inhibits tumours in an orthotopic xenograft model Mammary extracellular matrix (ECM) isolated from tamoxifen-treated 
rats inhibits tumours in an orthotopic xenograft model. (a) MDA-MB-
231 tumour cells mixed with tamoxifen ECM formed smaller tumours 
than when mixed with control ECM. n = 20 per group. (b) MDA-MB-
231 tumour cells mixed with 20 μg/ml fibronectin had a trend towards 
larger tumour size, consistent with fibronectin contributing to larger 
tumour size observed with control ECM. n = 10 per group.Available online http://breast-cancer-research.com/content/11/1/R5
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[46,47]. In another 3D model of dormancy, using several
breast cancer cell lines that exhibit dormancy in lungs of
xenografted mice, the transition from quiescence to prolifera-
tion was found to be dependent on fibronectin production, sig-
naling through β1 integrin, cytoskeletal reorganisation and the
formation of actin stress fibers [48]. Thus, the reconstitution
experiments reported here, where exogenous fibronectin par-
tially reverted the protective effect of tamoxifen ECM on
tumour cells in vitro and in a xenograft model of breast cancer,
implicate reduced levels of fibronectin as being a signal from
the microenvironment that contributes to tumour cell suppres-
sion. Our data indicate that this important growth promoting
ECM signal is negatively regulated by tamoxifen.
An additional prominent difference between tamoxifen-treated
and control rat mammary stroma was the reduction in matrix
proteolysis in the tamoxifen group. Proteolytic cleavage of
ECM proteins, which can unmask cryptic sites and release
fragments with bioactivity distinct from the parent molecule,
have important roles in immune modulation and cancer pro-
gression [49-51]. For example, in vitro collagen 1, fibronectin,
laminin and entactin derived peptides exhibit chemotactic
activity for inflammatory cells [49,52]. These previously pub-
lished studies are consistent with our data showing macro-
phage number was reduced in tamoxifen-treated mammary
glands, in vitro macrophage motility suppressed by tamoxifen
matrix and macrophage motility stimulated by the addition of
exogenous fibronectin and denatured collagen; ECM proteins
prominent in control mammary matrix. The observation that
tamoxifen treatment reduces mammary macrophage number is
intriguing because macrophages have been demonstrated to
be required for the rapid proliferative phase that occurs with
pubertal gland expansion [53]. In addition, macrophages are
implicated in numerous events associated with cancer pro-
gression, including enhanced breast tumour cell motility,
increased ECM remodeling, and blood vessel development
[53-55]. In women, breast cancers with a macrophage infil-
trate have a poorer prognosis, supporting the hypothesis that
macrophages are promoters of breast cancer [56]. Our data
extends these observations to suggest that inhibition of ECM
remodeling and macrophage recruitment are components of
the quiescent/dormant mammary microenvironment.
Tamoxifen treatment was also associated with an apparent
inhibition of LN5 γ2 chain cleavage because the level of about
a 25 kD proteolytic fragment of γ2 was reduced with tamoxifen
treatment. It has previously been demonstrated that mem-
brane type 1 (MT1)-MMP cleaves the rat γ2 chain to release
about a 30 kD fragment containing EGF-like repeats [57]. This
LN5 fragment binds to EGF receptors and stimulates breast
tumour cell scattering and migration. A similar proteolytic
cleavage site and bioactive γ2 fragment has been identified in
human LN5 [51]. The apparent ability of tamoxifen to reduce
the amount of this pro-tumourigenic LN5 fragment is additional
support for suppression of ECM turnover being important for
gland quiescence.
Collagen type 1 chains α-1(I) and α-2(I), components of fibril-
lar collagen, were identified in the isolated ECM by proteomic
analysis. Further, fibrillar collagen, detected in tissue sections
by Sirius red F3B staining, was observed at higher levels in
tamoxifen-treated glands than in control glands. This observa-
tion is somewhat perplexing because high levels of fibrillar col-
lagen are a component of reactive stroma around tumours and,
in vivo, breast cancer tumour cells have been observed to
migrate along collagen fibrils during metastasis [58,59]. As
with fibronectin and laminin, mammary collagen 1 cleavage
was decreased with tamoxifen treatment (Figure 4b). Thus,
slower matrix turnover may account for the high levels of fibril-
lar collagen observed with tamoxifen, but this remains to be
determined. Collagen turnover has been correlated with a
tumour permissive stroma, whereas inhibition of collagen turn-
over has been shown to delay mammary tumour progression
and metastasis [60,61]. Using human melanoma cells, cell-
cycle arrest was induced by fibrillar collagen [62]. The ques-
tion of whether mammary epithelial cell contact with fibrillar
collagen similarly restricts proliferation has not been evalu-
ated.
Our proteomic analysis identified several proteoglycans
present in mammary ECM including decorin, lumican, perle-
can, biglycan, mimecan and periostin. These proteoglycans
have roles in collagen assembly, fibrosis, wound healing and
cancer [63]. The roles of these ECM proteins in normal and
transformed mammary tissue are largely unknown, and these
proteins remain interesting candidates for further study.
The pleiotrophic response of the mammary stroma to
tamoxifen treatment suggests that tamoxifen influences the
expression of a master regulator of stromal function. Research
by other groups indicates that tumour growth factor (TGF) β,
which acts on fibroblasts, immune and endothelial cells, in
addition to epithelial cells, is a candidate regulator. In
tamoxifen-sensitive breast tumour cells, growth inhibition has
been shown to be mediated by activation of TGFβ [64]. Fur-
ther, the ability of tumour cells to upregulate TGFβ and its
receptor TβRII predict drug sensitivity [28]. The question of
whether TGFβ mediates the response to tamoxifen in normal
glandular epithelium, as reported here, is unknown. Another
question unresolved by our study is whether the response of
the stroma to tamoxifen is direct or indirect. ER-positive mam-
mary fibroblasts have been described and, in our study, a small
percentage of the mammary fibroblasts were found by immu-
nohistochemistry to be ERα or ERβ positive (data not shown).
Direct evidence for breast tumour fibroblasts modulating
tamoxifen sensitivity in tumour cells has recently been reported
[65]. In that study, using a 3D co-culture model, MCF-7 cells
mixed with Erα-positive/progesterone receptor (PR)-positive
fibroblasts were growth inhibited by tamoxifen, whereas MCF-Breast Cancer Research    Vol 11 No 1    Hattar et al.
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7 cells co-cultured with Erα-negative/PR-negative fibroblasts
exhibited decreased tamoxifen sensitivity [65]. That study is
highly supportive of tumour fibroblasts being direct targets of
tamoxifen.
Conclusions
In summary, in the normal mammary gland, a homeostatic bal-
ance appears to occur between ECM synthesis and turnover
resulting in the regulated release of bioactive ECM fragments.
One potential function of these ECM fragments is the recruit-
ment of macrophages for immune surveillance. Based on our
in vitro and in vivo studies, we find that the ECM turnover and
macrophage recruitment associated with the normal mammary
microenvironment is supportive of tumour cell progression.
Tamoxifen treatment was found to shift this balance toward
suppression of fibronectin synthesis, reduced ECM turnover,
accumulation of fibrillar collagen and reduced macrophage
infiltrate, resulting in a microenvironment that was suppressive
to breast tumour cells. Cumulatively, these data implicate sup-
pression of ECM turnover as being critical for a quiescent
mammary microenvironment and possibly tumour dormancy.
Also, these data suggest the compelling possibility that the
microenvironment may be part of the response to a variety of
physiological and drug interventions that are chemoprotective,
and that by characterising stromal changes induced by these
agents, important insight into tumour cell dormancy can be
obtained.
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